Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar 20;21(6):2144.
doi: 10.3390/ijms21062144.

Modulation of NLRP3 Inflammasome through Formyl Peptide Receptor 1 (Fpr-1) Pathway as a New Therapeutic Target in Bronchiolitis Obliterans Syndrome

Affiliations

Modulation of NLRP3 Inflammasome through Formyl Peptide Receptor 1 (Fpr-1) Pathway as a New Therapeutic Target in Bronchiolitis Obliterans Syndrome

Ramona D'Amico et al. Int J Mol Sci. .

Abstract

Chronic rejection is the major leading cause of morbidity and mortality after lung transplantation. Bronchiolitis obliterans syndrome (BOS), a fibroproliferative disorder of the small airways, is the main manifestation of chronic lung allograft rejection. We investigated, using transgenic mice, the mechanisms through which the deficiency of IL-1β/IL-18, Casp-1, or Fpr-1 genes could be protective in an experimental model of BOS, induced in mice by allogeneic heterotopic tracheal transplantation. Fpr-1 KO mice showed a marked reduction in histological markers of BOS and of mast cell numbers compared to other groups. Molecular analyses indicated that the absence of the Fpr-1 gene was able to decrease NF-κB nuclear translocation and modulate NLRP3 inflammasome signaling and the mitogen-activated protein kinase (MAPK) pathway in a more significant way compared to other groups. Additionally, Fpr-1 gene deletion caused a reduction in resistance to the apoptosis, assessed by the TUNEL assay. Immunohistochemical analyses indicated changes in nitrotyrosine, PARP, VEGF, and TGF-β expression associated with the pathology, which were reduced in the absence of the Fpr1 gene more so than by the deletion of IL-1β/IL-18 and Casp-1. We underline the importance of the NLRP3 inflammasome and the pathogenic role of Fpr-1 in experimental models of BOS, which is the result of the modulation of immune cell recruitment together with the modulation of local cellular activation, suggesting this gene as a new target in the control of the pathologic features of BOS.

Keywords: bronchiolitis obliterans syndrome; inflammasome; inflammation.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest

Figures

Figure 1
Figure 1
Histopatology evaluation and mast cell density in IL-1β/IL-18 KO, Casp-1 KO, and Fpr-1 KO: Histological evaluation of tracheal transplantation: wild-type (WT) (A), IL-1β/IL-18 KO (B), Casp-1 KO (C), Fpr-1 KO (D). Masson trichrome staining of the graft: WT (E), IL-1β/IL-18 KO (F), Casp-1 KO (G), Fpr-1 KO (H). Evaluation of mast cell degranulation by toluidine blue: WT (I), IL-1β/IL-18 KO (J), Casp-1 KO (K), Fpr-1 KO (L). Histopathologic score (M). For histological analyses, n = 5 animals from each group were employed. A p-value less than 0.05 was considered significant. ## p < 0.01 versus the WT group.
Figure 2
Figure 2
Effects of the absence of IL-1β/IL-18, Casp-1, and Fpr-1 on the NRLP3 inflammasome pathway. Western blots and, respectively, the densitometric analysis of NRLP3 (A,A’) and ASC (B,B’). For Western blot analyses, n = 5 animals from each group were employed. A p-value less than 0.05 was considered significant. # p < 0.05 versus the WT group, ### p < 0.001 versus the WT group.
Figure 3
Figure 3
Effects of the absence of IL-1β/IL-18, Casp-1, and Fpr-1 on the NF-κB pathway and iNOS expression. Western blots and, respectively, the densitometric analysis of IkB-α (A,A’), NF-kB p65 (B,B’), and iNOS (C,C’). For Western blot analyses, n = 5 animals from each group were employed. A p-value less than 0.05 was considered significant. ## p < 0.01 versus the WT group, and ### p < 0.001 versus the WT group.
Figure 4
Figure 4
Effects of the absence of IL-1β/IL-18, Casp-1, and Fpr-1 on Nitrotyrosine formation and PARP activation. Immunohistochemistry evaluation of nitrotyrosine expression: WT (A), IL-1β/IL-18 KO (B), Casp-1 KO (C), Fpr-1 KO (D), densitometric analysis (E). Immunohistochemistry evaluation of PARP expression: WT (F), IL-1β/IL-18 KO (G), Casp-1 KO (H), Fpr-1 KO (I), densitometric analysis (J). Yellow arrows point the positive cells. For immunohistochemistry, n = 5 animals from each group were employed. A p-value less than 0.05 was considered significant. ### p < 0.001 versus the WT group.
Figure 5
Figure 5
Effects of the absence of IL-1β/IL-18, Casp-1, and Fpr-1 on apoptosis. TUNEL staining of tracheal transplantation: WT (A), IL-1β/IL-18 KO (B), Casp-1 KO (C), Fpr-1 KO (D), graphical quantification (E). For TUNEL staining, n = 5 animals from each group were employed. A 20× magnification is shown (50-µm scale bar). A p-value less than 0.05 was considered significant. ### p < 0.001 versus the WT group.
Figure 6
Figure 6
Effects of the absence of IL-1β/IL-18, Casp-1, and Fpr-1 on growth factor expression. Immunohistochemistry evaluation of VEGF expression: WT (A), IL-1β/IL-18 KO (B), Casp-1 KO (C), Fpr-1 KO (D), densitometric analysis (E). Immunohistochemistry evaluation of TGF-β expression: WT (F), IL-1β/IL-18 KO (G), Casp-1 KO (H), Fpr-1 KO (I), densitometric analysis (J). Yellow arrows point the positive cells. For immunohistochemistry, n = 5 animals from each group were employed. A p-value less than 0.05 was considered significant. ### p < 0.001 versus the WT group.
Figure 7
Figure 7
Effects of the absence of IL-1β/IL-18, Casp-1, and Fpr-1 on the mitogen-activated protein kinase (MAPK) pathway. Western blots and, respectively, the densitometric analysis of p-ERK 1/2 (A,A’) and p-p38 (B,B’). For Western blot analyses, n = 5 animals from each group were employed. A p-value less than 0.05 was considered significant. # p < 0.05 versus the WT group, ### p < 0.001 versus the WT group.

Similar articles

Cited by

References

    1. Trulock E.P., Christie J.D., Edwards L.B., Boucek M.M., Aurora P., Taylor D.O., Dobbels F., Rahmel A.O., Keck B.M., Hertz M.I. Registry of the international society for heart and lung transplantation: Twenty-fourth official adult lung and heart-lung transplantation report-2007. J. Heart Lung Transpl. 2007;26:782–795. doi: 10.1016/j.healun.2007.06.003. - DOI - PubMed
    1. Chan A., Allen R. Bronchiolitis obliterans: An update. Curr. Opin. Pulm. Med. 2004;10:133–141. doi: 10.1097/00063198-200403000-00008. - DOI - PubMed
    1. Yousem S.A. Lymphocytic bronchitis/bronchiolitis in lung allograft recipients. Am. J. Surg. Pathol. 1993;17:491–496. doi: 10.1097/00000478-199305000-00008. - DOI - PubMed
    1. Shigenobu T., Ohtsuka T., Shimoda M. The prevention of tracheal graft occlusion using pioglitazone: A mouse tracheal transplant model study. Transpl. Immunol. 2019;53:21–27. doi: 10.1016/j.trim.2018.12.002. - DOI - PubMed
    1. Akindipe O., Fernandez-Bussy S., Jantz M., Lu L., Deem A., Swafford W., Staples E., Baz M. Obliterative bronchiolitis in lung allografts removed at retransplant for intractable airway problems. Respirology. 2009;14:601–605. doi: 10.1111/j.1440-1843.2009.01513.x. - DOI - PubMed

MeSH terms